The long-acting monoclonal antibody nirsevimab (Beyfortus) protects children younger than 2 years from respiratory syncytial virus (RSV) infection for up to 1 year but may not do so beyond that period, suggests a large real-world study published…
Nirsevimab prevents RSV cases in young kids for 1 year but maybe not beyond, data suggest
